Nivolumab outperformed the drug brentuximab vedotin (Adcetris), extending progression-free survival by 94% to one year versus 86%. Photo by Erubiel Flores/Pixabay The widely used immunotherapy drug nivolumab (Opdivo) is safer and more effective in treating adults and children with advanced Hodgkin lymphoma than the targeted therapy now used as standard of care, new clinical trial results show. Nivolumab outperformed the drug brentuximab vedotin (Adcetris), extending progression-free survival by 94% to one year versus 86%. Advertising Nivolumab also produced significantly fewer side effects than brentuximab vedotin, which was the first new…
Read More